CRISPR-Cas9 has moved germline modification from speculative fiction to clinical possibility. In 2018, He Jiankui edited the CCR5 gene in human embryos, crossing a threshold that bioethicists had debated for decades. The technical capacity to alter heritable human DNA now outpaces the philosophical frameworks we need to evaluate it. We are, in a very real sense, making decisions about the future of human biology before we have agreed on the principles that should govern those decisions.

The standard ethical discourse divides neatly into therapeutic applications—correcting genetic diseases like sickle cell anemia or Huntington's—and enhancement applications, which aim to push human capacities beyond species-typical norms. This distinction, inherited from medical ethics, carries enormous normative weight. It determines which interventions receive public funding, which gain regulatory approval, and which provoke moral outrage. But as Hans Jonas warned, the scope of human technological power now demands an ethics commensurate with that power—an ethics that extends responsibility across generations.

What follows is a philosophical framework for evaluating germline modification that takes seriously three interrelated challenges: the coherence of the treatment-enhancement distinction, the limits of parental authority over future persons, and the distributive justice implications of a world where genetic advantage becomes purchasable. Each of these threads reveals that genetic enhancement is not merely a bioethical issue. It is a question about what kind of species we intend to become, and who gets to decide.

The distinction between treating disease and enhancing normal function appears intuitive. Correcting a mutation that causes cystic fibrosis looks categorically different from engineering a child for superior memory retention. Medical ethics has long relied on this boundary: therapy restores normal functioning, enhancement exceeds it. But the philosophical foundations of this distinction erode under scrutiny, and the consequences of its instability are profound.

The concept of species-typical functioning, as articulated by Norman Daniels and others, anchors the therapy side of the line. Disease is departure from the statistical norm of human biological capacity. But statistical norms are not moral norms. The average human lifespan was once thirty-five years; we do not consider extending it to eighty an enhancement. Myopia affects roughly a third of the global population—correcting it with LASIK is therapy, but the sheer prevalence of the condition makes 'normal functioning' a moving and culturally contingent target.

More fundamentally, the therapy-enhancement distinction presupposes a fixed human nature against which deviations can be measured. This is precisely the assumption that germline modification destabilizes. If we can edit the genome, the reference class of 'normal human biology' becomes a choice rather than a given. What counts as a disease and what counts as a feature of the human condition becomes, in part, a design decision. The boundary between treatment and enhancement is not discovered in nature—it is constructed through social consensus, and that consensus is historically variable.

Consider the case of genetic predispositions to depression or low stress tolerance. These fall in a gray zone where the medical model struggles. They are not monogenic diseases with clear pathology, yet they impose significant suffering. If a germline edit could raise a child's baseline resilience, is that therapy or enhancement? The answer depends entirely on where we draw the line of normal functioning—and drawing that line is an exercise in values, not biology.

None of this means the distinction is useless. It serves important regulatory and heuristic functions. But it cannot bear the philosophical weight that the enhancement debate places on it. Any serious framework for evaluating germline modification must acknowledge that the treatment-enhancement boundary is a pragmatic convention, not a metaphysical fact, and must therefore seek additional principles to guide decisions that fall on either side of a line that was never sharp to begin with.

Takeaway

The line between fixing a disease and improving a person depends on a definition of 'normal' that is itself a human construction—one that germline editing forces us to consciously redraw rather than passively inherit.

Parents already make countless decisions that shape their children's lives—choosing schools, neighborhoods, diets, cultural exposures. Liberal societies grant broad parental discretion on the grounds that parents generally act in their children's interests and that family autonomy serves important social functions. But genetic enhancement introduces a qualitative shift in the nature of parental choice. Selecting a school is reversible; editing a genome is not. The decisions made at the embryonic stage become constitutive features of the person who emerges.

Joel Feinberg's concept of the child's right to an open future provides the strongest philosophical framework for evaluating this shift. Feinberg argued that children possess rights that are held in trust until they can exercise them—rights that parents must not foreclose. Choosing a child's career violates this right. But does choosing their genetic endowment? The answer depends on whether genetic traits constrain or expand future possibility. Engineering a child for extraordinary musical ability might open certain futures while narrowing others, embedding a parental vision of the good life into the child's very biology.

The deeper problem is one of consent and identity. The person affected by a germline edit does not yet exist at the time the decision is made. They cannot consent, refuse, or negotiate. And unlike environmental interventions, genetic modifications become part of the self in a way that is difficult to conceptually separate from the person. If a child is engineered for high intelligence, they cannot later choose to have been otherwise. The modification is not something that happened to them—it is, in part, what makes them who they are.

This creates what we might call the authorship paradox. The enhanced individual owes aspects of their identity to deliberate parental design rather than to the genetic lottery. Whether this constitutes a harm is deeply contested. Jürgen Habermas argued that it does—that being designed by another person fundamentally compromises one's sense of autonomy and self-authorship. Others counter that the genetic lottery is not inherently more dignifying than parental choice, and that enhancement might actually expand autonomy by providing greater capacities.

What is clear is that germline enhancement extends parental authority into a domain where its legitimacy is genuinely uncertain. The asymmetry is stark: parents bear the power but not the consequences; children bear the consequences but had no voice. Any defensible ethics of genetic enhancement must establish principled limits on parental design—limits that protect not just the welfare of future persons, but their capacity to define themselves on their own terms.

Takeaway

When a parent's choice becomes embedded in the child's genome, the distinction between shaping a life and authoring a person collapses—and with it, the easy assumption that parental love justifies parental design.

Even if the treatment-enhancement distinction could be stabilized and parental authority appropriately constrained, genetic enhancement confronts a third challenge that may prove the most politically intractable: distributive justice. Advanced germline modification will be expensive. Like most emerging technologies, it will be available first to the wealthy. If genetic enhancement delivers real advantages—higher cognitive capacity, greater disease resistance, extended healthspan—then unequal access will translate biological advantage into heritable social stratification of an unprecedented kind.

This is not merely an extension of existing inequality. Economic privilege already correlates with better nutrition, education, and healthcare. But these advantages, however unjust, remain environmental and in principle remediable. Genetic enhancement would inscribe advantage into the genome itself, creating what Lee Silver provocatively termed a GenRich class—a population whose biological superiority is literally inherited. The feedback loop is vicious: genetic advantage produces economic advantage, which funds further genetic enhancement, which deepens the biological divide.

John Rawls's difference principle—that inequalities are justified only if they benefit the least advantaged—provides one lens for evaluation. Under this framework, genetic enhancement is permissible only if its benefits trickle down. But the dynamics of positional goods complicate this analysis. If cognitive enhancement raises the bar for competitive success, those without enhancements are made relatively worse off even if their absolute condition does not change. The enhanced set a new standard that the unenhanced cannot meet, not through any failure of effort, but through lack of access to a technology they could not afford.

Some theorists argue that the solution is universal access—publicly funded genetic enhancement as a basic entitlement. This approach takes the justice concern seriously but raises its own difficulties. Who decides which enhancements become standard? A state-administered enhancement program carries echoes of eugenics that are not merely rhetorical but structurally real. The line between ensuring equal access and imposing genetic conformity is thinner than liberal democracies might wish.

The distributive challenge reveals that genetic enhancement cannot be evaluated as a private consumer choice. It is a collective action problem with species-level stakes. If some enhance and others cannot, we risk fracturing humanity into biological castes. If all enhance uniformly, we risk homogenizing the human genome in ways that reduce resilience and diversity. The philosopher's task here is not to provide a policy prescription but to insist that no framework for genetic enhancement is complete without a serious account of who benefits, who is excluded, and what kind of solidarity remains possible across a genetically stratified species.

Takeaway

When biological advantage becomes something you can purchase, inequality stops being a condition we might remedy and becomes a trait we pass down—making justice not just a social ideal but a question about the future architecture of the human species.

The ethics of genetic enhancement cannot be resolved by any single principle. The treatment-enhancement distinction is too unstable to serve as a bright line. Parental authority, however well-intentioned, reaches its philosophical limits when it shapes the very identity of future persons. And distributive justice demands that we confront enhancement not as a private choice but as a structural force capable of remaking human social relations from the genome up.

What is needed is not a prohibition or a permission, but a philosophical infrastructure—a set of conceptual tools adequate to the scale of the decisions we are beginning to make. Hans Jonas called for an ethics of responsibility proportional to technological power. Germline modification is precisely the kind of power he envisioned: irreversible, transgenerational, and laden with consequences we cannot fully predict.

The question is not whether humanity will modify its own genome. The technical trajectory makes that increasingly likely. The question is whether we will do so with the philosophical seriousness the act demands—or stumble forward, governed by market logic and parental aspiration, into a future we chose without understanding what we were choosing.